Georgina Fernandes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Georgina Fernandes has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Claire Thorne
UCL Great Ormond Street Institute of Child Health University College London London UK
4 shared publications - Heather Bailey
University College London
3 shared publications - Annalisa Sandcroft
Univ West Indies, Dept Child & Adolescent Hlth, Kingston, Jamaica
2 shared publications - Carlo Giaquinto
University of Padova
2 shared publications - Celia Dana Claire Christie
Faculty of Medical Sciences, Department of Child and Adolescent Health (Pediatric Infectious Diseases, Epidemiology and Public Health), University of the West Indies, Mona, Kingston 7, Jamaica
2 shared publications - Elisa Ruiz-Burga
University College London, Institute of Global Health, London, UK
2 shared publications
Latest Publications
- Open Access
- 8 November 2026
- Published by Wiley in HIV Medicine
Pregnancy and neonatal outcomes after prenatal exposure to dolutegravir: Data from a European cohort collaboration
Objective: We aimed to assess ‘real‐world’ pregnancy and neonatal outcomes following prenatal dolutegravir (DTG) use in a European setting. Methods: We conducted a pooled analysis of individual‐patient data from seven observational studies. Pregnancies with DTG exposure any time from the periconception period (≤6 completed gestational weeks) were included. Congenital anomalies were assessed using criteria defined by the World Health Organization International Classification of Diseases: Tenth Revision (ICD‐10) and the European Network of population‐based registries for the epidemiological surveillance of congenital anomalies (EUROCAT). Results: Of 827 pregnancies, there were 764 live births, 37 miscarriages, 21 terminations and five stillbirths. No congenital anomalies were identified in the five stillborn infants. One termination was due to an identified congenital anomaly. Excluding four infants with chromosomal abnormalities, 34 live‐born infants had 37 anomalies. There were no central nervous system abnormalities. Live birth prevalence of congenital anomalies was 4.4% (95% CI 3.0, 6.1) according to ICD‐10; for infants with earliest DTG exposure in the periconception period, later in the first trimester and in the second/third trimester, prevalence was 4.7% (22/470), 2.6% (1/38) and 4.1% (11/265), respectively. Prevalence according to EUROCAT classification was 3.5% (95% CI 2.3, 5.0) overall. In live‐born singletons with earliest exposure at periconception/first trimester and second/third trimesters, 13.6% (66/485) and 13.7% (32/255) were preterm and 9.7% (46/474) and 6.5% (16/246) were small for gestational age, respectively. Conclusions: Our data on prenatal DTG use do not demonstrate increased risk of congenital anomalies compared to expected rates. Ongoing monitoring is needed to exclude association with rare anomalies.
- 8 November 2026
- Published by Wiley in HIV Medicine
Open AccessPregnancy and neonatal outcomes after prenatal exposure to dolutegravir: Data from a European cohort collaboration
Objective: We aimed to assess ‘real‐world’ pregnancy and neonatal outcomes following prenatal dolutegravir (DTG) use in a European setting. Methods: We conducted a pooled analysis of individual‐patient data from seven observational studies. Pregnancies with DTG exposure any time from the periconception period (≤6 completed gestational weeks) were included. Congenital anomalies were assessed using criteria defined by the World Health Organization International Classification of Diseases: Tenth Revision (ICD‐10) and the European Network of population‐based registries for the epidemiological surveillance of congenital anomalies (EUROCAT). Results: Of 827 pregnancies, there were 764 live births, 37 miscarriages, 21 terminations and five stillbirths. No congenital anomalies were identified in the five stillborn infants. One termination was due to an identified congenital anomaly. Excluding four infants with chromosomal abnormalities, 34 live‐born infants had 37 anomalies. There were no central nervous system abnormalities. Live birth prevalence of congenital anomalies was 4.4% (95% CI 3.0, 6.1) according to ICD‐10; for infants with earliest DTG exposure in the periconception period, later in the first trimester and in the second/third trimester, prevalence was 4.7% (22/470), 2.6% (1/38) and 4.1% (11/265), respectively. Prevalence according to EUROCAT classification was 3.5% (95% CI 2.3, 5.0) overall. In live‐born singletons with earliest exposure at periconception/first trimester and second/third trimesters, 13.6% (66/485) and 13.7% (32/255) were preterm and 9.7% (46/474) and 6.5% (16/246) were small for gestational age, respectively. Conclusions: Our data on prenatal DTG use do not demonstrate increased risk of congenital anomalies compared to expected rates. Ongoing monitoring is needed to exclude association with rare anomalies.
- Open Access
- 23 October 2024
- Published by Wiley in HIV Medicine
- Vol. 26 (2) , 207-217
HIV postnatal prophylaxis and infant feeding policies vary across Europe: results of a Penta survey
Objectives: This survey was conducted to describe current European postnatal prophylaxis (PNP) and infant feeding policies with the aim of informing future harmonized guidelines.Methods: A total of 32 senior clinicians with relevant expertise, working in 20 countries within the European Region, were invited to complete a REDCap questionnaire between July and September 2023.Results: Twenty‐three of the 32 invited paediatricians responded, representing 16/20 countries. There were multiple respondents from the same country for Italy (n = 5), the UK (n = 2), Germany (n = 2) and France (n = 2). All countries use risk stratification to guide PNP regimen selection. Nine out of 16 countries reported three risk categories, six out of 16 reported two, and one country reported differences in categorization. Criteria used to stratify risk varied between and within countries. For the lowest risk category, the PNP regimen reported ranged from no PNP to up to four weeks of one drug; the drug of choice reported was zidovudine, apart from one country which reported nevirapine. For the highest risk category, the most common regimen was zidovudine/lamivudine/nevirapine (20/23 respondents); regimen duration varied from two to six weeks with variation in recommended dosing. Guidelines support breastfeeding for infants born to people living with HIV in eight out of 16 countries; in the other eight, guidelines do not support/specify.Conclusions: Guidelines and practice for PNP and infant feeding vary substantially across Europe and within some countries, reflecting the lack of robust evidence. Effort is needed to align policies and practice to reflect up‐to‐date knowledge to ensure the vertical transmission risk is minimized and unnecessary infant HIV testing and PNP avoided, while simultaneously supporting families to make informed decisions on infant feeding choice.
- 23 October 2024
- Published by Wiley in HIV Medicine
- Vol. 26 (2) , 207-217
Open AccessHIV postnatal prophylaxis and infant feeding policies vary across Europe: results of a Penta survey
Objectives: This survey was conducted to describe current European postnatal prophylaxis (PNP) and infant feeding policies with the aim of informing future harmonized guidelines.Methods: A total of 32 senior clinicians with relevant expertise, working in 20 countries within the European Region, were invited to complete a REDCap questionnaire between July and September 2023.Results: Twenty‐three of the 32 invited paediatricians responded, representing 16/20 countries. There were multiple respondents from the same country for Italy (n = 5), the UK (n = 2), Germany (n = 2) and France (n = 2). All countries use risk stratification to guide PNP regimen selection. Nine out of 16 countries reported three risk categories, six out of 16 reported two, and one country reported differences in categorization. Criteria used to stratify risk varied between and within countries. For the lowest risk category, the PNP regimen reported ranged from no PNP to up to four weeks of one drug; the drug of choice reported was zidovudine, apart from one country which reported nevirapine. For the highest risk category, the most common regimen was zidovudine/lamivudine/nevirapine (20/23 respondents); regimen duration varied from two to six weeks with variation in recommended dosing. Guidelines support breastfeeding for infants born to people living with HIV in eight out of 16 countries; in the other eight, guidelines do not support/specify.Conclusions: Guidelines and practice for PNP and infant feeding vary substantially across Europe and within some countries, reflecting the lack of robust evidence. Effort is needed to align policies and practice to reflect up‐to‐date knowledge to ensure the vertical transmission risk is minimized and unnecessary infant HIV testing and PNP avoided, while simultaneously supporting families to make informed decisions on infant feeding choice.
- Open Access
- 27 July 2022
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 6 (7) , e34423
Detection of Potential Arbovirus Infections and Pregnancy Complications in Pregnant Women in Jamaica Using a Smartphone App (ZIKApp): Pilot Evaluation Study
Background: There is growing evidence of the benefits of mobile health technology, which include symptom tracking apps for research, surveillance, and prevention. No study has yet addressed arbovirus symptom tracking in pregnancy. Objective: This study aimed to evaluate the use of a smartphone app (ZIKApp) to self-report arbovirus symptoms and pregnancy complications and to assess compliance with daily symptom diaries during pregnancy in a cohort of women in an arbovirus-endemic, subtropical, middle-income country (Jamaica). Methods: Pregnant women aged ≥16 years, having a smartphone, and planning on giving birth at the recruiting center were enrolled between February 2020 and July 2020. ZIKApp comprised a daily symptom diary based on algorithms to identify potential episodes of arbovirus infection and pregnancy complications. Sociodemographic, epidemiological, and obstetric information was collected at enrollment, with additional review of medical records, and users’ perception was collected through an exit survey. Descriptive analyses and logistic regression analysis of possible factors associated with diary adherence were performed. Results: Of the 173 women enrolled, 157 (90.8%) used ZIKApp for a median duration of 155 (IQR 127-173) days until pregnancy end, 6 (3.5%) used the app for 34 years versus those aged 25 to 29 years (adjusted odds ratio 3.14, 95% CI 1.10-8.98) and 2-fold higher odds for women with tertiary versus secondary education (adjusted odds ratio 2.26, 95% CI 1.06-4.83). Of the 161 women who ever made a diary entry, 5454 individual symptom reports were made (median 17 per woman; IQR 4-42; range 0-278); 9 (5.6%) women reported symptom combinations triggering a potential arbovirus episode (none had an adverse pregnancy outcome) and 55 (34.2%) reported painful uterine contractions or vaginal bleeding, mainly in the month before delivery. Overall, 51.8% (71/137) of the women rated the app as an excellent experience and were less likely to be poor diary adherers (P=.04) and 99.3% (138/139) reported that the app was easy to understand and use. Conclusions: This pilot found a high adherence to ZIKApp. It demonstrated the feasibility and usability of the app in an arbovirus-endemic region, supporting its future development to contribute to surveillance and diagnosis of arbovirus infections in pregnancy and to optimize maternal care.
- 27 July 2022
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 6 (7) , e34423
Open AccessDetection of Potential Arbovirus Infections and Pregnancy Complications in Pregnant Women in Jamaica Using a Smartphone App (ZIKApp): Pilot Evaluation Study
Background: There is growing evidence of the benefits of mobile health technology, which include symptom tracking apps for research, surveillance, and prevention. No study has yet addressed arbovirus symptom tracking in pregnancy. Objective: This study aimed to evaluate the use of a smartphone app (ZIKApp) to self-report arbovirus symptoms and pregnancy complications and to assess compliance with daily symptom diaries during pregnancy in a cohort of women in an arbovirus-endemic, subtropical, middle-income country (Jamaica). Methods: Pregnant women aged ≥16 years, having a smartphone, and planning on giving birth at the recruiting center were enrolled between February 2020 and July 2020. ZIKApp comprised a daily symptom diary based on algorithms to identify potential episodes of arbovirus infection and pregnancy complications. Sociodemographic, epidemiological, and obstetric information was collected at enrollment, with additional review of medical records, and users’ perception was collected through an exit survey. Descriptive analyses and logistic regression analysis of possible factors associated with diary adherence were performed. Results: Of the 173 women enrolled, 157 (90.8%) used ZIKApp for a median duration of 155 (IQR 127-173) days until pregnancy end, 6 (3.5%) used the app for 34 years versus those aged 25 to 29 years (adjusted odds ratio 3.14, 95% CI 1.10-8.98) and 2-fold higher odds for women with tertiary versus secondary education (adjusted odds ratio 2.26, 95% CI 1.06-4.83). Of the 161 women who ever made a diary entry, 5454 individual symptom reports were made (median 17 per woman; IQR 4-42; range 0-278); 9 (5.6%) women reported symptom combinations triggering a potential arbovirus episode (none had an adverse pregnancy outcome) and 55 (34.2%) reported painful uterine contractions or vaginal bleeding, mainly in the month before delivery. Overall, 51.8% (71/137) of the women rated the app as an excellent experience and were less likely to be poor diary adherers (P=.04) and 99.3% (138/139) reported that the app was easy to understand and use. Conclusions: This pilot found a high adherence to ZIKApp. It demonstrated the feasibility and usability of the app in an arbovirus-endemic region, supporting its future development to contribute to surveillance and diagnosis of arbovirus infections in pregnancy and to optimize maternal care.
- Open Access
- 22 October 2021
- Published by JMIR Publications Inc. in JMIR Preprints
The ZIKApp for detection of potential arbovirus infections and pregnancy complications in pregnant women in Jamaica: a pilot study (Preprint)
BACKGROUND Evidence of the benefits of mHealth technology including symptom tracking Apps for research, surveillance and prevention is growing, including for arboviruses and for pregnancy interventions. No study has yet addressed arbovirus symptom tracking in pregnancy. OBJECTIVE To evaluate the use of a smartphone app (“ZIKApp”) designed to self-report arbovirus symptoms and pregnancy complications, and to assess compliance with daily symptom diaries until the end of pregnancy in a cohort of women in an arbovirus endemic, subtropical, middle-developing country (Jamaica). METHODS Pregnant women aged 16 and over, having a smartphone, and planning on delivering at the recruiting centre were enrolled from an antenatal clinic in February-July 2020. The ZIKApp comprised a daily symptom diary based on algorithms to identify potential episodes of arboviral infection and/or pregnancy complications that triggered automatic notifications to participants. Socio-demographic, epidemiological and obstetric information was collected at enrolment, with additional review of medical records; and users' perception through an exit survey. Descriptive analyses and logistic regression of possible factors associated with diary adherence were performed. RESULTS Of 173 women enrolled, 90% (157) used ZIKApp for median duration of 155 days between enrolment and pregnancy end, six used the app for < 7days and 10 exited the study early. For each successive 30 day period from enrolment up to 150 days post-enrolment, 77-82% of these 157 women completed their daily symptom diary; 32-36% did so on the same day. Overall, 50 (31.9%) women had ‘good adherence’ to diary reporting (i.e. completed same day or 2-3 days later for ≥80% of days enrolled). There were three-fold higher odds of good adherence for participants >34 years versus those 25-29 (AOR 3.14 95%CI 1.10-8.98) and two-fold higher odds for women with tertiary versus secondary education (AOR 2.26, 95% CI 1.06-4.83). Of 161 women who ever made a diary entry, a total of 5454 individual symptom reports were made (median 17 per woman, max 278). Nine (5.3%) women reported symptom combinations triggering a “potential arbovirus episode” (none had an adverse pregnancy outcome) and 55 (32.9%) women reported painful uterine contractions, or vaginal bleeding, mainly in the month before delivery. The exit survey showed that 52% (71/137) of women rated the App as an excellent experience and were less likely to be poor diary adherers (p=.04); 138/139 women reported that the App was easy to understand and to use. CONCLUSIONS In the era of telemedicine and mHealth, adherence to the ZIKApp in pregnancy was high. The pilot has demonstrated the feasibility and usability of the App in an arbovirus-endemic region, supporting its future development to contribute to surveillance and diagnosis of arboviral infections in pregnancy and promise for implementation by direct treatment and care teams to optimise maternal care. CLINICALTRIAL
- 22 October 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe ZIKApp for detection of potential arbovirus infections and pregnancy complications in pregnant women in Jamaica: a pilot study (Preprint)
BACKGROUND Evidence of the benefits of mHealth technology including symptom tracking Apps for research, surveillance and prevention is growing, including for arboviruses and for pregnancy interventions. No study has yet addressed arbovirus symptom tracking in pregnancy. OBJECTIVE To evaluate the use of a smartphone app (“ZIKApp”) designed to self-report arbovirus symptoms and pregnancy complications, and to assess compliance with daily symptom diaries until the end of pregnancy in a cohort of women in an arbovirus endemic, subtropical, middle-developing country (Jamaica). METHODS Pregnant women aged 16 and over, having a smartphone, and planning on delivering at the recruiting centre were enrolled from an antenatal clinic in February-July 2020. The ZIKApp comprised a daily symptom diary based on algorithms to identify potential episodes of arboviral infection and/or pregnancy complications that triggered automatic notifications to participants. Socio-demographic, epidemiological and obstetric information was collected at enrolment, with additional review of medical records; and users' perception through an exit survey. Descriptive analyses and logistic regression of possible factors associated with diary adherence were performed. RESULTS Of 173 women enrolled, 90% (157) used ZIKApp for median duration of 155 days between enrolment and pregnancy end, six used the app for < 7days and 10 exited the study early. For each successive 30 day period from enrolment up to 150 days post-enrolment, 77-82% of these 157 women completed their daily symptom diary; 32-36% did so on the same day. Overall, 50 (31.9%) women had ‘good adherence’ to diary reporting (i.e. completed same day or 2-3 days later for ≥80% of days enrolled). There were three-fold higher odds of good adherence for participants >34 years versus those 25-29 (AOR 3.14 95%CI 1.10-8.98) and two-fold higher odds for women with tertiary versus secondary education (AOR 2.26, 95% CI 1.06-4.83). Of 161 women who ever made a diary entry, a total of 5454 individual symptom reports were made (median 17 per woman, max 278). Nine (5.3%) women reported symptom combinations triggering a “potential arbovirus episode” (none had an adverse pregnancy outcome) and 55 (32.9%) women reported painful uterine contractions, or vaginal bleeding, mainly in the month before delivery. The exit survey showed that 52% (71/137) of women rated the App as an excellent experience and were less likely to be poor diary adherers (p=.04); 138/139 women reported that the App was easy to understand and to use. CONCLUSIONS In the era of telemedicine and mHealth, adherence to the ZIKApp in pregnancy was high. The pilot has demonstrated the feasibility and usability of the App in an arbovirus-endemic region, supporting its future development to contribute to surveillance and diagnosis of arboviral infections in pregnancy and promise for implementation by direct treatment and care teams to optimise maternal care. CLINICALTRIAL